Dr. Kiran Dhillon Highlights Cancer Vaccine Urgency in JAMA Oncology Viewpoint

The Cancer Vaccine Institute (CVI) is proud to highlight a recent JAMA Oncology Viewpoint co‑authored by our Executive Director, Dr. Kiran Dhillon, and Dr. Lennard Lee of the University of Oxford, outlining why the time for cancer vaccines is now.

For decades, the U.S. has invested in the science, infrastructure, and talent needed to make cancer vaccines possible. Early clinical data now show that these vaccines are safe, effective, and already providing meaningful benefits to patients. Newer generations of vaccines – powered by advances in genomic sequencing, AI‑assisted antigen discovery, and mRNA and DNA platforms – hold even greater promise.

Cancer vaccine research has reached a pivotal moment. The UK is moving with remarkable speed and national coordination, demonstrating what strong federal commitment can achieve. As the Viewpoint emphasizes, this is a critical moment for renewed support in the U.S. Without it, decades of investment and momentum are at risk.

Most importantly, patients are waiting. At the CVI, we remain committed to advancing clinical trials, pioneering vaccine development, and translating cutting‑edge science into therapies that can prevent recurrence, intercept or prevent cancer, and transform cancer care.

The call for action is now – and the CVI is ready to answer.

JAMA Oncology Viewpoint.pdf

Download PDF • 82KB